- Home
- REPX vs PRAX Comparison
REPX vs PRAX Comparison
Compare REPX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- PRAX
- Stock Information
- Founded
- REPX 2016
- PRAX 2015
- Country
- REPX United States
- PRAX United States
- Employees
- REPX N/A
- PRAX N/A
- Industry
- REPX Oil & Gas Production
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- REPX Energy
- PRAX Health Care
- Exchange
- REPX Nasdaq
- PRAX Nasdaq
- Market Cap
- REPX 608.2M
- PRAX 599.7M
- IPO Year
- REPX N/A
- PRAX 2020
- Fundamental
- Price
- REPX $25.84
- PRAX $33.79
- Analyst Decision
- REPX Strong Buy
- PRAX Strong Buy
- Analyst Count
- REPX 1
- PRAX 9
- Target Price
- REPX $47.00
- PRAX $123.33
- AVG Volume (30 Days)
- REPX 106.4K
- PRAX 570.3K
- Earning Date
- REPX 05-07-2025
- PRAX 05-12-2025
- Dividend Yield
- REPX 5.86%
- PRAX N/A
- EPS Growth
- REPX N/A
- PRAX N/A
- EPS
- REPX 4.26
- PRAX N/A
- Revenue
- REPX $410,181,000.00
- PRAX $8,553,000.00
- Revenue This Year
- REPX $7.75
- PRAX N/A
- Revenue Next Year
- REPX $2.95
- PRAX $789.73
- P/E Ratio
- REPX $6.07
- PRAX N/A
- Revenue Growth
- REPX 9.37
- PRAX 249.53
- 52 Week Low
- REPX $21.98
- PRAX $26.70
- 52 Week High
- REPX $37.55
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- REPX 45.25
- PRAX 43.73
- Support Level
- REPX $21.98
- PRAX $28.79
- Resistance Level
- REPX $24.72
- PRAX $30.88
- Average True Range (ATR)
- REPX 1.89
- PRAX 3.07
- MACD
- REPX -0.04
- PRAX 0.88
- Stochastic Oscillator
- REPX 48.13
- PRAX 56.05
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties, and Tennessee Properties, among others.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.